Inari Medical, Inc. (NASDAQ:NARI) Shares Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D grew its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 23.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,087 shares of the company’s stock after purchasing an additional 8,830 shares during the period. State of New Jersey Common Pension Fund D owned 0.08% of Inari Medical worth $1,901,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. GAMMA Investing LLC increased its holdings in shares of Inari Medical by 164.7% in the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after acquiring an additional 438 shares during the period. Nisa Investment Advisors LLC increased its holdings in shares of Inari Medical by 83.5% in the 2nd quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after acquiring an additional 435 shares during the period. Covestor Ltd increased its holdings in shares of Inari Medical by 30.2% in the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock worth $78,000 after acquiring an additional 376 shares during the period. Benjamin F. Edwards & Company Inc. increased its holdings in shares of Inari Medical by 39.4% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after acquiring an additional 522 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Inari Medical in the 2nd quarter worth about $104,000. 90.98% of the stock is owned by institutional investors and hedge funds.

Inari Medical Trading Up 2.7 %

NASDAQ:NARI opened at $50.56 on Monday. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $67.13. The company has a 50-day moving average of $45.19 and a 200-day moving average of $47.05. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of -37.45 and a beta of 0.96.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on NARI shares. Piper Sandler increased their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a report on Tuesday, October 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Inari Medical in a report on Tuesday, October 29th. Leerink Partners started coverage on shares of Inari Medical in a research note on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 target price on the stock. Stifel Nicolaus started coverage on shares of Inari Medical in a research note on Tuesday, September 17th. They set a “hold” rating and a $50.00 target price on the stock. Finally, Canaccord Genuity Group raised their target price on shares of Inari Medical from $71.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday, October 29th. Six research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $58.89.

Insiders Place Their Bets

In other Inari Medical news, Director William Hoffman sold 40,000 shares of the firm’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $45.02, for a total value of $1,800,800.00. Following the completion of the transaction, the director now directly owns 601,233 shares in the company, valued at $27,067,509.66. This trade represents a 6.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CFO Mitch C. Hill sold 3,000 shares of the firm’s stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $45.13, for a total transaction of $135,390.00. Following the completion of the transaction, the chief financial officer now owns 179,600 shares of the company’s stock, valued at approximately $8,105,348. The trade was a 1.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 126,000 shares of company stock worth $5,921,390 over the last ninety days. 10.60% of the stock is currently owned by company insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.